Jonathan D. Schwartz

Author

Also Known As

J D Schwartz, J Schwartz, J. D. Schwartz, J. Schwartz, J.D. Schwartz, Jonathan D Schwartz, Jonathan D. Schwartz, Jonathan Schwartz, Schwartz, J.D.

105

Publications

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Icahn School of Medicine at Mount Sinai Universitat Autònoma de Barcelona

About

Jonathan D. Schwartz is an author at Eli Lilly (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	6.3K
2	Health Sciences	10	10	1.3K
3	Cell Biology	3	3	290
4	Public Health	2	2	43
5	Cellular Therapies	1	1	170

Jonathan D. Schwartz

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial H. Wilke, Kei Muro, Eric Van Cutsem, The Lancet Oncology Surgical OncologyGastrointestinal OncologyMedicinePaclitaxel Versus PlaceboGastroenterology	2014	2.4K
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Charles S. Fuchs, Jiří Tomášek, Filip Dumitru, The Lancet Surgical OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicine	2013	2.2K
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, The Lancet Oncology OncologyHepatologyClinical TrialsRamucirumab Versus PlaceboPharmacotherapy	2015	829
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma Abby B. Siegel, E. Cohen, Allyson J. Ocean, Journal of Clinical Oncology	2008	506
Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung, Liver Transplantation	2004	460
Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/<i>neu</i> Howard Safran, David A. Iannitti, Ramesh K. Ramanathan, Cancer Investigation	2004	190
Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia Susana Navarro, Wei Wang, Rebeca Sánchez‐Domínguez, Nature Medicine Fanconi AnemiaCell TherapyNon-conditioned PatientsDevelopmental BiologyBone Marrow Failure	2019	170
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer Andrew X. Zhu, Richard S. Finn, Mary F. Mulcahy, Clinical Cancer Research	2013	164
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Annals of Oncology Advanced EsophagealSurgical OncologyEsophagusEsophageal CancerGastroesophageal Junction	2016	143
Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells Zhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, Clinical Cancer Research	2010	122

Page 1